Telixs TLX592 Shows Promise in Prostate Cancer Treatment

Telix Pharmaceuticals (ASX: TLX) completes CUPID, a Phase I study of TLX592, a targeted alpha therapy for prostate cancer. The study establishes a proof-of-concept for Telix’s RADmAb® antibody platform, showing rapid blood clearance and hepatic clearance, desirable for alpha therapy. The successful mass dose escalation study sets a dosing schedule for TLX592 using actinium-225.

Data supports advancement to a Phase I/II therapeutic study in H2 2024. TLX592, utilizing RADmAb® technology, accelerates blood clearance while maintaining target selectivity. The study, utilizing copper-64 (64Cu) for PET imaging, demonstrates accelerated blood kinetics compared to standard antibodies, with similar biodistribution. No serious adverse events were observed. Telix plans to advance TLX592 to a therapeutic study with 225Ac in H2 2024, complementing its prostate cancer therapy portfolio.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com